Collectively, 76 patients had concurrent NSCLC driver mutations, including 49 with EGFR, 16 with KRAS, 4 with ERBB2 amplifications, 3 with MET alterations, 3 with ALK fusions, and 2 with ROS1 fusions (Fig. 2a, Additional file 2: Table S3). Here, MET is linked to non-small cell lung carcinoma.